What should be monitored regularly in patients receiving methotrexate therapy?

In patients receiving methotrexate therapy, it is crucial to monitor complete blood counts (CBC) and liver function tests regularly. Methotrexate is an immunosuppressive medication often used in the treatment of conditions like rheumatoid arthritis and certain types of cancer.

Monitoring the CBC helps to assess for potential myelosuppression, which is a common side effect of methotrexate. This can lead to leukopenia, thrombocytopenia, and anemia, all of which can significantly increase the risk of infections and other complications.

Liver function tests are also essential because methotrexate can be hepatotoxic, leading to elevated liver enzymes and potential liver damage. Regular monitoring can help detect any liver issues early, allowing for timely intervention or adjustments in therapy.

The other options are less relevant to the specific monitoring needs of patients on methotrexate. For instance, while respiratory rate, blood glucose levels, and electrolyte balance may be monitored in other contexts, they do not address the key risks associated with methotrexate therapy as comprehensively as CBC and liver function tests do.